{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:12:01Z","timestamp":1774278721822,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jns.2026.125752","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:16:51Z","timestamp":1768004211000},"page":"125752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Corticosteroids in myasthenia gravis: Rethinking oral corticosteroid therapy"],"prefix":"10.1016","volume":"481","author":[{"given":"U.K.","family":"Misra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125752_bb0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of oral steroid therapy for myasthenia gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.125752_bb0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"Mann","year":"1976","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2026.125752_bb0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2026.125752_bb0020","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2026.125752_bb0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10072-016-2556-3","article-title":"Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients","volume":"37","author":"Cioncoloni","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2026.125752_bb0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"issue":"5","key":"10.1016\/j.jns.2026.125752_bb0035","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40120-025-00796-w","article-title":"Use of corticosteroids in myasthenia gravis: expert opinion for daily management","volume":"14","author":"Mantegazza","year":"2025","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.jns.2026.125752_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jns.2026.125752_bb0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","article-title":"Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India","volume":"38","author":"Sonkar","year":"2017","journal-title":"J. Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.jns.2026.125752_bb0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"18","key":"10.1016\/j.jns.2026.125752_bb0055","article-title":"Appropriate use of steroids for patients with generalized myasthenia gravis: an international Delphi study","author":"Wiendl","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.jns.2026.125752_bb0060","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/pn-2025-004655","article-title":"Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)","volume":"25","author":"Jacob","year":"2025","journal-title":"Pract. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:24:22Z","timestamp":1774275862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2600033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":12,"alternative-id":["S0022510X2600033X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125752","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroids in myasthenia gravis: Rethinking oral corticosteroid therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125752"}}